126 related articles for article (PubMed ID: 7379441)
1. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
2. Massive propranolol metabolite retention during maintenance hemodialysis.
Stone WJ; Walle T
Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
[TBL] [Abstract][Full Text] [Related]
3. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
[TBL] [Abstract][Full Text] [Related]
4. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver.
Ring JA; Ghabrial H; Ching MS; Shulkes A; Smallwood RA; Morgan DJ
Drug Metab Dispos; 1995 Feb; 23(2):190-6. PubMed ID: 7736910
[TBL] [Abstract][Full Text] [Related]
5. N-dealkylation of propranolol in rat, dog, and man. Chemical and stereochemical aspects.
Nelson WL; Bartels MJ
Drug Metab Dispos; 1984; 12(3):345-52. PubMed ID: 6145562
[TBL] [Abstract][Full Text] [Related]
6. The influence of diltiazem versus cimetidine on propranolol metabolism.
Tateishi T; Ohashi K; Fujimura A; Ebihara A
J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Influence of aging on the oxidative and conjugative metabolism of propranolol.
Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A
Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155
[TBL] [Abstract][Full Text] [Related]
10. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
[TBL] [Abstract][Full Text] [Related]
11. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
[TBL] [Abstract][Full Text] [Related]
12. Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation.
Ghabrial H; Nand R; Stead CK; Smallwood RA; Morgan DJ
J Pharm Sci; 1994 Jul; 83(7):931-6. PubMed ID: 7965671
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.
Bianchetti G; Graziani G; Brancaccio D; Morganti A; Leonetti G; Manfrin M; Sega R; Gomeni R; Ponticelli C; Morselli PL
Clin Pharmacokinet; 1976; 1(5):373-84. PubMed ID: 1017154
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)lactic acid as a metabolite of propranolol in the rat, in man, and in the rat liver 9000 g supernatant fraction.
Talaat RE; Nelson WL
Drug Metab Dispos; 1986; 14(2):202-7. PubMed ID: 2870895
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of propranolol: a review.
Shand DG
Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
[TBL] [Abstract][Full Text] [Related]
16. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
[TBL] [Abstract][Full Text] [Related]
17. Nonlinear formation of propranolol metabolites in dogs after portacaval transpositions.
Lo MW; Pond SM; Effeney DJ; Silber BM; Riegelman S; Tozer TN
J Pharmacokinet Biopharm; 1984 Aug; 12(4):401-12. PubMed ID: 6527232
[TBL] [Abstract][Full Text] [Related]
18. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
Terao N; Shen DD
J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
[TBL] [Abstract][Full Text] [Related]
19. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
[TBL] [Abstract][Full Text] [Related]
20. In vitro cutaneous biotransformation of propranolol.
Cormier M; Ledger PW; Marty JP; Amkraut A
J Invest Dermatol; 1991 Sep; 97(3):447-53. PubMed ID: 1875045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
